The Latest Breaking News from Merck

The long-term prospects of Merck (MRK) look bright due to its latest acquisitions and solid drug pipeline. Therefore, investing in this stock could help generate substantial returns in the long run. Keep reading….

What you need to know… The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.33%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.30%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.06%. Stock indexes Monday posted moderate gains. An increase in...

Morning Markets June S&P 500 futures (ESM2 3) this morning are up +0.02%, and June Nasdaq 100 E-Mini futures (NQM2 3) are down -0.03%. U.S. stock index futures this morning are mixed. An increase in M&A activity is positive for stocks after Merck said it would acquire Prometheus Biosciences for...

Adding a personalized cancer vaccine to the blockbuster drug Keytruda kept more melanoma patients in remission than the immune therapy alone, co-developers Moderna Inc. and Merck & Co. said in their first detailed presentation of a key study.

Moderna stock rose Monday after European regulators granted its Merck-partnered personalized cancer vaccine a key designation.

Medical stocks are holding up amid economic and market uncertainty.

The maximum loss will occur if MRK closes above 115 on April 21.

Earth’s gravity makes it harder to cultivate the proteins needed to study diseases and pathogens. And although the cost of space travel is high, private enterprise is stepping in

An era of gray zone warfare and sabotage creates tough financial questions.